试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-05-03
Tocotrienol as a Nutritional Supplement in Patients With Advanced Lung Cancer
编号:NCT02644252登记状态:提前终止企业 / 申办者:Vejle Hospital
药物 / 成分:Day 1: Cisplatin 75 mg/m2、Day 1: Vinorelbine 25 mg/m2、Day 8: Capsule vinorelbine 50 mg/m2、Day 1: Carboplatin AUC=5
登记的停止原因(原文):The trial was ended prematurely because of a poor accrual rate
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-05-03
Biological-guided Metronomic Chemotherapy as Maintenance Strategy in Metastatic Colorectal Cancer
编号:NCT03158610登记状态:提前终止企业 / 申办者:Ruijin Hospital
药物 / 成分:Capecitabine
登记的停止原因(原文):Difficult to enrollment patient
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-05-03
A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of External Genital Warts
编号:NCT03158974登记状态:提前终止企业 / 申办者:ViroXis Corporation
药物 / 成分:East Indian Sandalwood Oil Cream
登记的停止原因(原文):Sponsor terminated study due to financial constraints.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-05-03
Magnesium Sulfate in the Prevention of Post-ERCP Pancreatitis.
编号:NCT03749590登记状态:提前终止企业 / 申办者:University Medicine Greifswald
药物 / 成分:Magnesium Sulfate、Placebo (NaCl 0,9%)
登记的停止原因(原文):The design of the MagPEP trial is no longer in compliance with the current state of science.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-05-03
Hydroxychloroquine for COVID-19
编号:NCT04342221登记状态:提前终止企业 / 申办者:University Hospital Tuebingen
药物 / 成分:Hydroxychloroquine Sulfate、Placebo
登记的停止原因(原文):Reduced acceptance of IMP
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-05-03
Clinical Study for the Treatment With Interferon-ß-1a (IFNß-1a) of COVID-19 Patients
编号:NCT04449380登记状态:提前终止企业 / 申办者:Emanuele Bosi
药物 / 成分:Interferon-ß-1a、Standard of Care (SOC)
登记的停止原因(原文):Futility
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-04-30
A Dose-finding Study of OPC-6535 in Patients With Active Ulcerative Colitis
编号:NCT00317356登记状态:提前终止企业 / 申办者:Otsuka Pharmaceutical Co., Ltd.
药物 / 成分:OPC-6535(Tetomilast)
登记的停止原因(原文):Efficacy was not cleared at US study
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-04-30
A Clinical Study To Investigate The Effectiveness And Safety Of Tanezumab In Treating Pain Associated With Endometriosis
编号:NCT00784693登记状态:提前终止企业 / 申办者:Pfizer
药物 / 成分:Tanezumab、Placebo
登记的停止原因(原文):Further recruitment into the study was ceased on 10th December 2009, not attributed to safety. All patients recruited in the study completed all study visits.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-04-30
Study of NC-6004 in Combination With 5-FU and Cetuximab in Patients With Head and Neck Cancer
编号:NCT02817113登记状态:提前终止企业 / 申办者:Orient Europharma Co., Ltd.
药物 / 成分:NC-6004、Cetuximab、5-FU
登记的停止原因(原文):Strategy change
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-04-30
Pneumococcal Conjugate Vaccine in Aging Renal Transplant
编号:NCT03802994登记状态:提前终止企业 / 申办者:VA Office of Research and Development
药物 / 成分:23 valent pneumococcal polysaccharide vaccine、13 valent conjugated pneumococcal vaccine、Peripheral blood sample
登记的停止原因(原文):Due to COVID pandemic further recruitment of subjects was unethical.
查看官方原始记录 ↗